Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607719 · ClinicalTrials.gov registry record · Phase 2
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
A Phase 2 study of Chronic Obstructive Pulmonary Disease, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05607719 is a Phase 2 study of Chronic Obstructive Pulmonary Disease that is actively recruiting participants, run by University of Miami. The registered enrollment target is 30 participants, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05607719, a Phase 2 study of Chronic Obstructive Pulmonary Disease, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The study objective is to determine whether an ICS added for 4 weeks to a baseline treatment with a Long-Acting Beta-adrenergic Agonist (LABA) and Long-Acting Muscarinic Antagonist (LAMA) combination improves pulmonary vascular endothelial function as assessed by the vasodilator response to inhaled albuterol (endothelium-dependent vasodilation) in stable COPD patients treated with a LABA/LAMA without an ICS for at least one month.
Conditions Studied
Interventions
- DRUG Bevespi
- DRUG Bretzri
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05607719
The ClinicalTrials.gov registry entry for NCT05607719 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (98% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 2 interventions - of which Bevespi is the first listed.
NCT05607719 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05607719 about?
NCT05607719 is a clinical study titled "Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD". The study objective is to determine whether an ICS added for 4 weeks to a baseline treatment with a Long-Acting Beta-adrenergic Agonist (LABA) and Long-Acting Muscarinic Antagonist (LAMA) combination improves pulmonary vascular endothelial function as assessed by the vasodilator response to inhaled ...
What is the current status of trial NCT05607719?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-04-11. Estimated completion is 2026-12-31.
What conditions does trial NCT05607719 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT05607719?
The interventions under investigation include: Bevespi (DRUG), Bretzri (DRUG).
Who is sponsoring clinical trial NCT05607719?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607719 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
RECRUITING · Phase 2
-
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
RECRUITING · Phase 2
-
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.